Chinese Bidder Draws Closer To Complete Genomics Buy

Law360, New York (January 14, 2013, 7:34 PM EST) -- After Chinese officials signed off Friday on Chinese company's bid for California-based gene sequencer Complete Genomics Inc., all eyes are on a Delaware court, where shareholder litigation continues, and on rival Illumina Inc., which has quietly withdrawn a topping offer it made in November.

BGI said it has obtained clearance from the National Development & Reform Commission, China's chief economic regulator, for its $3.15-per-share offer valuing Complete Genomics at about $108 million. The NDRC approval follows clearances from the Committee on Foreign Investment in the U.S. and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.